Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.

Trial Details

NCT ID
NCT07144254
Phase
PHASE1
Sponsor
Emory University
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Tegavivint
  • Gemcitabine
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Diagnosis:
  • Participants must have had histologic verification of osteosarcoma at original diagnosis or relapse.
  • All participants with relapsed or refractory osteosarcoma are eligible, provided they received front-line treatment with a regimen that contained a…
  • Disease Status:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →